Effective treatment of late-onset noninfectious pulmonary complication with ruxolitinib in an 8-year-old boy.

Maria Elisa Di CiccoEster Del TufoEva ParoloMariacristina MenconiSayla BernasconiChiara RomeiAlessandro Di GangiBeatrice MasiniDiego PeroniGabriella Casazza

Published in: ERJ open research (2021)

Ruxolitinib could be considered as an option in the treatment of LONIPCs in children when other treatments are ineffective. Spirometry is a valuable tool for both diagnosis and follow-up of LONIPCs in children. https://bit.ly/3BmOYfb.

Keyphrases

late onset
young adults
pulmonary hypertension
lung function
cystic fibrosis